1. Healos/Recombinant Human Growth and Differentiation Factor-5 Induces Posterolateral Lumbar Fusion in a New Zealand White Rabbit Model
- Author
-
Travis G. Maak, Quasai Hamouria, Jonathan N. Grauer, Bradley S. Raphael, Todd J. Albert, David P. Magit, Inneke Drespe, Nancy Trioano, and Gert K. Polzhofer
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Bone morphogenetic protein ,Transplantation, Autologous ,Iliac crest ,Collagen Type I ,New Zealand white rabbit ,Lumbar ,Growth Differentiation Factor 5 ,medicine ,Animals ,Orthopedics and Sports Medicine ,Bone Transplantation ,Lagomorpha ,biology ,business.industry ,Growth factor ,biology.organism_classification ,Recombinant Proteins ,Spine ,Surgery ,Durapatite ,Spinal Fusion ,medicine.anatomical_structure ,Bone Morphogenetic Proteins ,Bone Substitutes ,Models, Animal ,Female ,Rabbits ,Neurology (clinical) ,business ,Complication ,Type I collagen - Abstract
STUDY DESIGN Posterolateral lumbar spine fusions in New Zealand white rabbits. OBJECTIVE To evaluate the efficacy of recombinant human growth and differentiation factor-5 (rhGDF-5) lyophilized to a Healos carrier (cross-linked type I collagen with hydroxyapatite coating; DePuy Spine, Inc., Raynham, MA) in inducing fusion. SUMMARY OF BACKGROUND DATA Bone graft substitutes have become an area of considerable interest. rhGDF-5 is one such product. Limited lumbar preclinical studies have been performed with this product. METHODS Single-level, intertransverse process fusions were performed in 67 rabbits using iliac crest autograft (n = 13), Healos alone (n = 13), or 0.5, 1.0, or 1.5 mg/cc rhGDF-5 lyophilized to Healos (n = 13 per group). At 8 weeks, the rabbits were euthanized. Fusion masses were assessed. RESULTS There were 2 animals (3%) lost to complication. Manual palpation revealed fusion rates for autograft of 38% (5/13), Healos alone of 0% (0/13), and each of the Healos/rhGDF-5 groups of 100% (13/13). Histologic analyses were 95% sensitive and 95% specific for confirming fusion. Histologic differences were found among the treatment groups. CONCLUSIONS In this rabbit fusion model, Healos/rhGDF-5 induced fusion in 100% of the rabbits studied. This rate was significantly higher than the fusion rate induced by autograft (38%). Overall, these results support continued research of Healos/rhGDF-5 as a potential bone graft alternative.
- Published
- 2006